Beijing : China has approved the trial of its first ‘nasal spray vaccine’ to fight COVID-19. The trial of the first phase of this vaccine is expected to begin in November. This clinical trial will be done on 100 people. So far, more than nine million people have died worldwide due to this global epidemic spreading from China. According to the Chinese government mouthpiece Global Times, this is the first vaccine of its kind, approved by the National Medical Products Administration of China.
It has been developed by researchers from Hong Kong University and Beijing-based Wanatai Biological Pharmacy. Hong Kong University microbiologist Yuwen Kyong Wyeong said that this nasal vaccine provides double protection. It inactivates the coronavirus as well as the flu like N1H1. He also admitted that this vaccine may cause side effects like asthma and shortness of breath.
Meanwhile, World Health Organization chief scientist Dr. Soumya Swaminathan says that the agency is not too worried about the trial of the corona vaccine developed by Oxford University and pharmaceutical company AstraZeneca. She said that the interruption of the trial of the Oxford Vaccine has given the world an opportunity to understand that there are fluctuations in research. She also said that thousands and millions of tests need to be done to determine whether the vaccine is capable of protecting people from the disease.
Meanwhile, Chinese scientists have found in their studies that cats may also be prone to corona infection. The rate of infection has been found to be higher than earlier estimates. Researchers at the Huazhong Agricultural University of China have made this claim based on an analysis of blood samples of 102 cats. The presence of corona antibodies was detected in blood samples of 15 cats.